Evidence map›Paper›PMID 24390320›Full record

ArticleJournal of virology2014

Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase.

Jennifer L Fribourgh, Henry C Nguyen, Leslie S Wolfe, David C Dewitt, Wenyan Zhang, Xiao-Fang Yu, Elizabeth Rhoades, Yong Xiong

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.Protein science : a publication of the Protein Society · 2020
    Review
  10. Structural basis of antagonism of human APOBEC3F by HIV-1 Vif.Nature structural & molecular biology · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jennifer L FribourghDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, USA.
Henry C Nguyen
Leslie S Wolfe
David C Dewitt
Wenyan Zhang
Xiao-Fang Yu
Elizabeth Rhoades
Yong Xiong
Yale University · USJilin University · CNJohns Hopkins University · US

Funding

Skill Development for Diverse Scientific Careers: A New Course Predoctoral Program in Cellular and Molecular BiologyT32GM007223 · NIGMS · YALE UNIVERSITY · PI BASERGA, SUSAN J · 1985 to 2019
$31.0M
Structural Studies of HIV Vif and Its Cellular Binding PartnersR33AI078831 · NIAID · YALE UNIVERSITY · PI XIONG, YONG · 2010 to 2012
$1.1M
Structural Studies of HIV Vif and Its Cellular Binding PartnersR21AI078831 · NIAID · YALE UNIVERSITY · PI XIONG, YONG · 2008 to 2009
$441k
Identification of novel anti-HIV inhibitors based on Vif-E3 activityR21AI102798 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARKHAM, RICHARD B. · 2013 to 2014
$431k
NIAID NIH HHS AI078831NIAID NIH HHS R21 AI078831NIAID NIH HHS R21 AI102798NIAID NIH HHS R33 AI078831NIGMS NIH HHS T32 GM007223
6 · The paper itself

Abstract

unlabelledThe HIV-1 virion infectivity factor (Vif) targets the cellular cytidine deaminases APOBEC3G (A3G) and APOBEC3F (A3F) for degradation via the host ubiquitin-proteasome pathway. Vif recruits a cellular E3 ubiquitin ligase to polyubiquitinate A3G/F. The activity of Vif critically depends on the cellular core binding factor beta (CBFβ). In this study, we investigated the Vif-CBFβ interaction and the role of CBFβ in the E3 ligase assembly. Vif-CBFβ interaction requires an extensive region of Vif spanning most of its amino terminus and zinc finger region, and cullin 5 (Cul5) binding enhances the stability of the Vif-CBFβ interaction. Our results further demonstrate that CBFβ plays a critical role in facilitating Cul5 binding to the Vif/elongin B/elongin C complex. Vif, with or without bound substrate, is unable to bind Cul5 in the absence of CBFβ. These studies support the notion that CBFβ serves as a molecular chaperone to facilitate Vif-E3 ligase assembly. IMPORTANCE: The host antiviral restriction factors A3G/F inhibit viral replication. The HIV-1 protein Vif targets A3G/F for degradation. This immune evasion activity of Vif is dependent on the cellular factor CBFβ. Multiple regions of Vif are known to be important for Vif function, but the mechanisms are unclear. The studies described here provide important information about the Vif-CBFβ interaction interface and the function of CBFβ in E3 ligase assembly. In particular, our comprehensive Vif-CBFβ interface mapping results help to delineate the role of various Vif regions, determining if they are important for binding CBFβ or A3G/F. Furthermore, our studies reveal an important potential mechanism of CBFβ that has not been shown before. Our results suggest that CBFβ may serve as a molecular chaperone to enable Vif to adopt an appropriate conformation for interaction with the Cul5-based E3 ligase. This study advances our understanding of how CBFβ facilitates the Vif-mediated degradation of APOBEC3 proteins.

Indexed as

Cell LineCore Binding Factor beta SubunitCullin ProteinsElonginHIV-1HIV InfectionsHumansProtein BindingTranscription FactorsUbiquitin-Protein Ligasesvif Gene Products, Human Immunodeficiency VirusCore Binding Factor beta SubunitCUL5 protein, humanCullin ProteinsELOB protein, humanELOC protein, humanElonginTranscription FactorsUbiquitin-Protein Ligasesvif Gene Products, Human Immunodeficiency Virus

Identifiers

PMID24390320
PMCPMC3957930
OpenAlexW2139992011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.